- |||||||||| Avastin (bevacizumab) / Roche, Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Tecentriq (atezolizumab) / Roche
Enrollment open, Combination therapy, Metastases: Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Jan 9, 2018 P1/2, N=62, Recruiting, Initiation date: Sep 2017 --> Jan 2018 | Trial primary completion date: Mar 2020 --> Jul 2021 Active, not recruiting --> Recruiting
- |||||||||| Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment open, Trial initiation date: Entinostat Neuroendocrine (NE) Tumor (clinicaltrials.gov) - Dec 14, 2017 P2, N=40, Recruiting, Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Aug 2017 --> Jan 2018
- |||||||||| Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial primary completion date, Combination therapy, Epigenetic controller: MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 25, 2017 P1, N=63, Active, not recruiting, Trial primary completion date: Jul 2017 --> Jan 2021 Trial primary completion date: Dec 2005 --> Apr 2011
- |||||||||| Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial primary completion date, Combination therapy, Epigenetic controller: MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 16, 2017 P1, N=63, Active, not recruiting, Not yet recruiting --> Recruiting Trial primary completion date: Apr 2011 --> Dec 2005
- |||||||||| Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Opdivo (nivolumab) / BMS
Trial primary completion date, Metastases: Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. (clinicaltrials.gov) - Oct 7, 2017 P2, N=120, Recruiting, Trial primary completion date: Apr 2011 --> Dec 2005 Trial primary completion date: Aug 2017 --> Aug 2018
- |||||||||| Targretin oral (bexarotene oral) / ReXceptor, entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
Journal: Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies. (Pubmed Central) - Jul 19, 2017 Shared grade 3-4 non-hematologic toxicities included febrile neutropenia, bone pain, fatigue, and dyspnea. GM-CSF plus either BEX or ENT are well tolerated in resistant and refractory MDS and AML and showed modest clinical and biologic activity, most commonly HI-N.
- |||||||||| Avastin (bevacizumab) / Roche, Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Tecentriq (atezolizumab) / Roche
Enrollment closed, Trial initiation date, Combination therapy, Metastases: Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Jun 8, 2017 P1/2, N=62, Active, not recruiting, Clinicaltrials.gov identifier: NCT00866333 . Not yet recruiting --> Active, not recruiting | Initiation date: Jan 2017 --> May 2017
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment open, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, Epigenetic controller: Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents (clinicaltrials.gov) - Apr 6, 2017 P1b, N=27, Recruiting, N=165 --> 10 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Apr 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2017 --> Jun 2019
- |||||||||| Vesanoid (tretinoin) / Roche, entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
Journal: Combined treatment with epigenetic, differentiating, and chemotherapeutic agents cooperatively targets tumor-initiating cells in triple negative breast cancer. (Pubmed Central) - Apr 2, 2017 In this study, we found that combined treatment of TNBC xenografts with entinostat, ATRA, and doxorubicin (EAD) resulted in significant tumor regression and restoration of epigenetically silenced RAR-β expression...Finally, we demonstrate that patient-derived metastatic cells also responded to treatment with EAD. Collectively, our findings strongly suggest that entinostat potentiates doxorubicin-mediated cytotoxicity and retinoid-driven differentiation to achieve significant tumor regression in TNBC.
- |||||||||| Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Surgery, Metastases: ETCTN-9844: Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer (clinicaltrials.gov) - Feb 17, 2017 P1, N=45, Recruiting, This would help improve efficacy, drug tolerability and expand the horizon of these novel agents. Trial primary completion date: Jan 2017 --> Jun 2018
- |||||||||| Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment closed, Trial primary completion date, Combination therapy, Epigenetic controller, Metastases: Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov) - Feb 11, 2017 P1/2, N=45, Active, not recruiting, Trial primary completion date: Jan 2017 --> Jun 2018 Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Jun 2017
- |||||||||| Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment open, Trial initiation date, Epigenetic controller: Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (clinicaltrials.gov) - Feb 1, 2017 P1, N=36, Recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Jun 2017 Not yet recruiting --> Recruiting | Initiation date: Mar 2017 --> Dec 2016
- |||||||||| Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer (clinicaltrials.gov) - Jan 5, 2017 P1, N=15, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=30 --> 15 | Trial primary completion date: Dec 2016 --> Feb 2019
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment change, Trial initiation date, Trial primary completion date, Metastases: PEMDAC: Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye (clinicaltrials.gov) - Nov 28, 2016 P2, N=29, Not yet recruiting, Trial primary completion date: Jun 2016 --> Mar 2012 N=24 --> 29 | Initiation date: Jun 2016 --> Mar 2017 | Trial primary completion date: Mar 2018 --> Sep 2019
|